Weekly Insider Trading, July 10

Weekly introduction

Back to regular programming. This week, I cover transactions registered in the past two weeks. I also plan more formal updates of performance going forward. It will be a rough estimation though since I do not currently have a format on how to communicate exact entries and exits. More on that later in this article.

In the last update from July 1st, I wrote:

"we currently see a rapid rise in bearishness in indicators that usually should be interpreted as contrarian indicators, meaning even if next few days continue to be volatile, on a 20 day forward outlook, the market returns tend to be positive".

We can already see a more positive market. I expect it to continue these 20 days counting from July 1st, and then more selectively in names reporting earnings which will propel some stocks higher. But the overall market risks weakening once again post earnings.

Introduction to Weekly Insider Trading (for new readers)

Weekly Insider Trading from G-stock is the result of quantitative screening of insider trading, coupled with qualitative checks, to produce a list of companies with the most interesting cues. The screening process starts by looking at number and value of insider trades, if spread across insiders, their historic behavior and the value of current trade in comparison to existing shares owned. This produces a list of the most interesting companies to look at. The next step is to filter based on type of trades and the person trading. Purchases in a new issuance of stock or exercise of options are generally considered of lesser value than an open market purchase. Generally, the more spread across insiders, the better should be the signaling value. Within the insider category, officers are highest ranked, followed by directors and >10% owners. That said, nothing is binary, and continuous purchases of a >10% owner can be very supportive for price just like buybacks are. So, to summarize, simply looking at transaction values is not enough. Most of the time, insider transactions need to be put in context, quantitatively and qualitatively, only then can such transactions be of value for portfolio decisions.

Please note that the companies presented and information given should not be interpreted as a full picture view, or some fundamental analysis of the company. I am merely identifying insider trading patterns and looking at some basic info related to those companies, and if available adding analysis done in other articles directly linked to the company, to better score the value of such insider transactions. I strongly encourage everyone to do their own fundamental analysis of each company before investing.

Types of Insider transaction setup (of course any position is contingent on other screening factors as well)

Market opportunistic with

positive trend, Insiders increasing holdings in a correction in a stock with general uptrend (here I would buy and hold for some time, 1-6 months) Market opportunistic with

no trend, Insiders increasing holdings in a correction in a stock with a sideways trend (here, I would buy and sell on a reversal to mean or within 3 months if the stock is not moving)

Turnaround bet, Insiders increasing holdings in a stock in a sideways or downwards trend (higher risk, smaller position, event driven holding, max 6 months, smaller size).

Update of open and closed positions

Previously, I have stated that I would not always be recommending an exit point. In some cases, I have done so explicitly with a reasoning, perhaps due to an update of insider selling or other news significantly affecting the case. In other cases, I have just pointed out in a later article that these are the ones I have exited or these are the ones I am now long. I used that history to create the tables below. I will aim to be a bit more formal with this going forward. These tables are prices taken from the charts published/or closing price that day, so they do not account for any entry (or exit) strategies employed etc.

*For example, the largest drawdown in the table is Clean Energy Fuels (NASDAQ:CLNE), but I clearly stated in the article:

"What happened in 2012 and 2015 after the spikes are cause for concerns though, there should be a lot of overhead supply, therefore I would want to see a slight pullback and then ride it for a quick 10-20%."

I actually bought some CLNE on Tuesday, July 10, at 2.8 something.

Still in the table, I used the price at time of writing, so aspects like that underestimate the true returns.

Also, it is the equally weighted return, and both in words and tables, I have expressed stronger opinion on some stocks than others. Especially, the "turnaround" cases should always be treated more cautiously than other cases. The avg. return, open and closed trades, is about 9%. That is lower than my actual account insider portfolio returns of about +25% YTD, so there is some underestimating of the true returns. I believe most of that difference comes from the low-digit returns of about 5-7 companies that I only held for a week and which were small bets (low probability insider setups) entry prices have usually been better than closing prices due to waiting for a pullback and averaging purchases. Weighting of individual companies:

img src="https://static.seekingalpha.com/uploads/2018/7/11/6570121-1531303776202781.jpg" width="640" data-width="640" data-height="1044" data-og-image-twitter_small_card="true" data-og-image-twitter_large_card="true" data-og-image-twitter_image_post="true" data-og-image-msn="true" data-og-image-facebook="true" data-og-image-google_news="true" data-og-image-google_plus="true" data-og-image-linkdin="true"">>

This article's insider trading stocks

I have looked at the SEC reported insider transactions over the last two months (report date). The final list includes companies based on the insider activity rank, which might or might not lead to an immediate action.

Company

Ticker

Insider activity

Longer term insider score

Company Fundamentals

Chart Technicals

Type of Setup

Action

Intrexon Corp.

XON

0

0

0

0

-

-

REV Group

REV

+

0

+

+

"Turnaround"

Buy +

Dermira

DERM

+

0

0

0

"Turnaround"

Buy -

OPKO Health

OPKO

+

+

-

0

"Turnaround"

*

Honorary mention: EGN (Energen Corp). Carl Icahn has recently increased his stake to 7.5%. In May, Icahn and Corvex Management - run by former Icahn Capital executive Keith Meister - said they may try to buy EGN, which they believe is undervalued.

Intrexon (XON)

Summary

Intrexon has failed to make its stockholders happy over the years. There have been some extremely large insider transactions in the company, especially the one last week, but the signaling value of that is rather low being a secondary offering. In addition to that, after looking at Kirk Randal's earlier purchases in XON, activity in other companies, like Aquabounty Tech (AQB) and ZIOPHARM Oncology (ZIOP), where he also made very large investments which have turned out to be equally poor. Therefore, the value screening might scream buy here, but I will await action from other insiders before I engage.

Basic company Info

Intrexon Corp. is a biotechnology company, which engages in the business of synthetic biology. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The firm offers UltraVector, RheoSwitch, cell systems informatics, protein engineering, and antibody discovery.

Industry

Healthcare

Market cap

2 B

Employees

1000

P/S

8.6

Founded

1998

P/E

-

Website

www.dna.com

P/CF

-

Insider trading

Kirk Randal has deep pockets and has made purchases consistently on the way down in price. Purchases from other insiders, especially officers, are rather bleak, both in comparison and by itself. Most also only show up once in the list below, and no one except Kirk has made purchases in 2018 even though the stock has traded 50% lower than 2017 levels.

Name

Insider Type

Trade date

Buy/Sell

Price

Value

Own. Chg

Kirk Randal J

CEO, 10%

2018-07-03

Buy

$13.37

+$99,999,992

13%

Kirk Randal J

CEO, 10%

2018-01-19

Buy

$12.50

+$12,500,000

2%

Last Andrew J.

COO

2017-11-13

Buy

$12.10

+$24,200

100%

Gupta Vinita D

Dir

2017-08-22

Buy

$17.61

+$52,830

106%

Shapiro Robert B

Dir

2017-08-22

Buy

$17.50

+$49,883

2%

Kindler Jeffrey B

Dir

2017-08-11

Buy

$18.32

+$99,661

8%

Last Andrew J.

COO

2017-08-14

Buy

$19.99

+$39,980

New

Kirk Randal J

CEO, 10%

2017-08-11

Buy

$18.85

+$2,499,981

0%

Nimrodi Nir

SVP-Corporate Development

2017-08-11

Buy

$18.75

+$63,169

84%

Lehr Donald P.

GC

2017-08-11

Buy

$18.33

+$20,053

4%

Perez Jeffrey Thomas

SVP, IP Affairs

2017-08-11

Buy

$17.89

+$17,890

9%

Mitchell Dean J

Dir

2017-08-11

Buy

$18.33

+$91,640

38%

Kirk Randal J

CEO, 10%

2016-12-13

Buy

$28.90

+$1,000,113

0%

Liffman Joel D

SVP, Finance

2016-12-12

Buy

$28.62

+$243,265

6%

Hassan Fred

Dir

2016-12-01

Buy

$29.02

+$200,266

New

Nimrodi Nir

SVP-Corporate Development

2016-08-29

Buy

$26.12

+$104,484

New

Kirk Randal J

CEO, 10%

2016-05-13

Buy

$23.92

+$1,000,574

0%

Kirk Randal J

CEO, 10%

2015-12-11

Buy

$29.85

+$3,715,801

0%

Kirk Randal J

CEO, 10%

2015-12-07

Buy

$30.69

+$7,289,642

0%

Krishnan Krish S

COO

2015-12-02

Sell

$35.66

-$745,371

-20%

Krishnan Suma

SVP--Product Development

2015-12-02

Sell

$35.66

-$745,371

-20%

Kirk Randal J

CEO, 10%

2015-01-27

Buy

$27.00

+$15,000,012

1%

Chart and technical

Not much positive to say about the chart. While the swings are big, I do not see this as a beginning of a new uptrend. Would only trade this for a mean reversion from lower levels

img src="https://static.seekingalpha.com/uploads/2018/7/6570121_15313037004828_rId7_thumb.jpg" data-width="640" data-height="320" data-og-image-twitter_small_card="true" data-og-image-twitter_large_card="true" data-og-image-twitter_image_post="true" data-og-image-msn="true" data-og-image-facebook="true" data-og-image-google_news="true" data-og-image-google_plus="true" data-og-image-linkdin="true"">>

Fundamentals

Following disappointing Q1 earnings, the stock dropped from the highs of the year (around $20) to current levels ($13-17).

Dec-17

Dec-16

Dec-15

Dec-14

Dec-13

Dec-12

Total Revenues

231

191

174

72

43

14

y/y %

21.0%

10.0%

141.4%

67.6%

210.9%

72.5%

Gross profit

168

129

110

53

-16

14

Gross margin %

73%

68%

63%

73%

-37%

100%

EBITDA

-104.3

-121.7

-138.1

-64.8

-57

-67.4

EBITDA %

-45%

-64%

-80%

-90%

-133%

-488%

Net income

-117

-187

-85

-82

-57

-104

Cash and equivalents

68

63

136

43

50

10

Free cash flow

-151

-88

23

-26

-60

-69

Seeking Alpha and other articles

No recent articles are available - articles available dated 2016 and earlier. Seems like investors have given up?

REV Group (REVG)

Summary

Several REVG officers have made their firsts purchases since the IPO. Historically, the company has shown solid growth numbers but failed to reach expectations during Q2. Following that release, the stock dropped sharply from already having had a bad run since the Q1 report (even though it beat expectations). Fundamentals look good both historically, but the company has so far in 2018 faced cost pressures, which it is now trying to mitigate through price increases. I believe the insiders' actions point to the belief of continued growth and that this was a bump in the road… (trucks…). Given the low valuation (2018 P/E 14), for being a "Turnaround", I rate this with high conviction.

Basic company Info

REV Group, Inc. engages in the manufacture, distribution, and designs of specialty vehicles and related aftermarket parts and services. It operates through the following segments: Fire and Emergency, Commercial, Recreation, and Corporate and Other. The Fire and Emergency segment offers fire apparatus, and ambulance products. The Commercial segment involves in transit and shuttle buses, type A school buses, mobility vans, and other specialty vehicles such as sweepers and terminal trucks distributed both through dealers, and direct. The Recreation segment covers motorized RV products sold to brand-loyal, repeat customers who purchase through dealers. The Corporate and Other segment includes corporate office expenses, stock-based compensation, results of insignificant operations, intersegment eliminations, income, and expenses.

Industry

Industrial Equipment & Components

Market cap

1.1 B

Employees

7.000

P/S

0.45

Founded

2010

P/E

20

Website

www.revgroup.com

P/CF

25

Insider trading

In March 2018, the CEO made his first purchase since the IPO, a significant purchase of +2M$, almost doubling total holdings. In June 2018, the Chief HR Officer, CFO and one director have made purchases around $15-16. This after the drop early in June when the stock dropped as low as 13$ following the disappointing Q1 results. Neither of these insiders has trades registered in any other companies.

Name

Insider Type

Trade date

Buy/Sell

Price

Value

Own. Chg

Nolden Dean J

CFO

2018-06-26

Buy

$16.49

+$164,934

49%

Nolden Dean J

CFO

2018-06-26

Buy

$16.49

+$16,493

5%

Canan John

Dir

2018-06-25

Buy

$16.04

+$80,845

381%

Stephens Barbara H

CHRO

2018-06-13

Buy

$15.56

+$15,556

8%

Stephens Barbara H

CHRO

2018-03-23

Buy

$20.96

+$20,962

8%

Sullivan Timothy W

CEO

2018-03-13

Buy

$22.52

+$2,252,500

92%

American Industrial Partners Capital Fund IV LP

10%

2017-10-17

Sell

$26.09

-$282,122,661

-24%

Marvin Kim A

Dir

2017-10-17

Sell

$26.09

-$283,330,794

-24%

Cusumano Dino M

Dir

2017-10-17

Sell

$26.09

-$283,330,794

-24%

Fish Justin

Dir

2017-10-17

Sell

$26.09

-$25,701

-24%

Rotroff Joel M.

Dir

2017-10-17

Sell

$26.09

-$25,701

-24%

Phillips Thomas B

COO

2017-09-13

Sell/Option

$26.73

-$267,302

-100%

Rotroff Joel M.

Dir

2017-02-09

Sell

$20.54

-$2,342

-3%

Fish Justin

Dir

2017-02-09

Sell

$20.54

-$2,342

-3%

Marvin Kim A

Dir

2017-02-09

Sell

$20.54

-$25,744,313

-3%

Cusumano Dino M

Dir

2017-02-09

Sell

$20.54

-$25,744,313

-3%

American Industrial Partners Capital Fund IV LP

10%

2017-02-09

Sell

$20.54

-$25,634,534

-3%

Chart and technical

REVG was trading around 28 for most of 2017 but then dropped in Q1 2018 and started trending downwards. Trading down to $13 was a washout and if the company keeps its FY2018 promises, then the stock should continue to rebound. Serious resistance comes in around 20.img src="https://static.seekingalpha.com/uploads/2018/7/6570121_15313037004828_rId9_thumb.jpg" data-width="640" data-height="320" data-og-image-twitter_small_card="true" data-og-image-twitter_large_card="true" data-og-image-twitter_image_post="true" data-og-image-msn="true" data-og-image-facebook="true" data-og-image-google_news="true" data-og-image-google_plus="true" data-og-image-linkdin="true"">>

Fundamentals

The historical FY numbers look very positive, with accelerating revenue growth rate and increasing gross margin and EBITDA %. But in Q2, the revenue growth fell to +12% and gross margin was also 12%, lower due to commodity price inflation.

For 2018, the guidance now is Revenues of 2.5B (+10%), Net income of 80M vs. 31M prior year. This would imply a 2018 P/E of around 14.

Dec-17

Dec-16

Dec-15

Dec-14

Total Revenues

2,268

1,926

1,735

1,721

y/y %

17.7%

11.0%

0.8%

Gross profit

295

230

182

163

Gross margin %

13%

12%

10%

9%

EBITDA

125

100.5

85

53.3

EBITDA %

6%

5%

5%

3%

Net income

31

30

23

2

Cash and equivalents

18

11

5

0

Free cash flow

-21

38

10

-6

Seeking Alpha and other articles

As usual, SA provides excellent articles from other authors. Here is one from March 2018, after the Q1 beat but negative stock reaction, taking it to around $20.

REV Group: Buying The Dip, Long-Term Improvement Trends Remain Intact

Dermira Inc. (DERM)

Summary

Dermira is a biotech company with what I consider very interesting products. The stock is down 70% from the highs last year at a time the news flow could be turning around and the CEO has stepped in and made the first purchases (increasing holdings by approx. 1/3), not only by him but by basically any insider in the last 4 years. The cash position is strong, leaving us with a very low valuation, given the potential in approved products and potential news triggers in successful study results.

Basic company Info

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.

Industry

Biotechnology

Market cap

460 M

Employees

162

P/S

122

Founded

2010

P/E

-

Website

www.dermira.com

P/CF

-

Insider trading

Try to find buy's in the table below… Not much to be found until recently, where the CEO increased his holdings by approx. one-third, after the stock dropped hard following the failure of the Acne study.

Name

Insider Type

Trade date

Buy/Sell

Price

Value

Own. Chg

Wiggans Thomas G

CEO, COB

2018-07-09

Buy

$10.00

+$119,951

6%

Wiggans Thomas G

CEO, COB

2018-07-02

Buy

$8.71

+$119,998

7%

Wiggans Thomas G

CEO, COB

2018-06-25

Buy

$9.84

+$119,586

7%

Wiggans Thomas G

CEO, COB

2018-06-18

Buy

$10.10

+$119,954

7%

Bauer Eugene A

Chief Medical Officer

2018-03-02

Sell/Option

$25.00

-$62,500

-8%

Bauer Eugene A

Chief Medical Officer

2018-03-01

Sell/Option

$25.32

-$12,658

-2%

Cohen David E

Dir

2018-03-01

Sell

$25.85

-$15,510

-2%

Bauer Eugene A

Chief Medical Officer

2018-02-01

Sell/Option

$28.55

-$85,642

-9%

Cohen David E

Dir

2018-02-01

Sell

$28.87

-$17,322

-2%

Bauer Eugene A

Chief Medical Officer

2018-01-02

Sell/Option

$27.07

-$81,210

-9%

Griffith Christopher M.

SVP Head Corp. Dev., Strategy

2018-01-02

Sell/Option

$27.05

-$499,354

-30%

Cohen David E

Dir

2018-01-02

Sell

$28.03

-$16,818

-2%

Bauer Eugene A

Chief Medical Officer

2017-12-18

Sell

$27.34

-$82,011

-9%

Wiggans Thomas G

CEO, COB

2017-12-13

Sell/Option

$27.51

-$137,566

-3%

Cohen David E

Dir

2017-12-01

Sell

$25.49

-$15,294

-2%

Wiggans Thomas G

CEO, COB

2017-11-02

Sell/Option

$27.52

-$137,608

-3%

Cohen David E

Dir

2017-11-01

Sell

$26.82

-$16,092

-2%

Bauer Eugene A

Chief Medical Officer

2017-10-11

Sell

$30.04

-$225,300

-18%

Wiggans Thomas G

CEO, COB

2017-10-10

Sell/Option

$27.52

-$137,606

-3%

Cohen David E

Dir

2017-10-02

Sell

$26.99

-$16,194

-2%

Wiggans Thomas G

CEO, COB

2017-09-18

Sell/Option

$27.51

-$261,336

-6%

Cohen David E

Dir

2017-09-01

Sell

$23.56

-$14,136

-2%

Cohen David E

Dir

2017-08-28

Sell

$23.81

-$14,286

-2%

Craves Fred B

Dir, 10%

2017-08-10

Buy

$23.03

+$690,930

1%

Wiggans Thomas G

CEO, COB

2017-08-01

Sell/Option

$27.58

-$13,791

0%

Bauer Eugene A

Chief Medical Officer

2017-07-05

Sell

$30.00

-$75,008

-6%

Wiggans Thomas G

CEO, COB

2017-07-03

Sell/Option

$29.06

-$145,298

-3%

Bauer Eugene A

Chief Medical Officer

2017-06-20

Sell

$30.01

-$75,032

-6%

Wiggans Thomas G

CEO, COB

2017-06-01

Sell/Option

$27.52

-$137,623

-3%

Griffith Christopher M.

SVP Head Corp. Dev., Strategy

2017-05-15

Sell/Option

$27.07

-$35,516

-3%

Wiggans Thomas G

CEO, COB

2017-05-01

Sell/Option

$33.66

-$269,272

-5%

Bauer Eugene A

Chief Medical Officer

2017-05-01

Sell

$33.65

-$84,116

-5%

Ringo William R

Dir

2017-05-01

Sell/Option

$34.06

-$17,030

-100%

Griffith Christopher M.

SVP Head Corp. Dev., Strategy

2017-04-17

Sell/Option

$33.97

-$44,267

-3%

Ringo William R

Dir

2017-04-03

Sell/Option

$34.03

-$17,015

-100%

Bauer Eugene A

Chief Medical Officer

2017-04-03

Sell

$33.53

-$83,836

-5%

Wiggans Thomas G

CEO, COB

2017-04-03

Sell/Option

$33.49

-$267,949

-5%

Griffith Christopher M.

SVP Head Corp. Dev., Strategy

2017-03-15

Sell/Option

$35.79

-$46,630

-3%

Wiggans Thomas G

CEO, COB

2017-03-03

Sell/Option

$37.60

-$150,416

-3%

Bauer Eugene A

Chief Medical Officer

2017-03-01

Sell

$33.61

-$84,032

-5%

Wiggans Thomas G

CEO, COB

2017-03-01

Sell/Option

$33.54

-$368,945

-63%

Ringo William R

Dir

2017-03-01

Sell/Option

$35.09

-$17,547

-100%

Griffith Christopher M.

SVP Head Corp. Dev., Strategy

2017-02-15

Sell/Option

$30.79

-$40,118

-3%

Ringo William R

Dir

2017-02-15

Sell/Option

$32.00

-$16,000

-100%

Bauer Eugene A

Chief Medical Officer

2017-02-14

Sell

$30.00

-$45,153

-3%

Wiggans Thomas G

CEO, COB

2017-02-01

Sell/Option

$29.35

-$146,764

-3%

Bauer Eugene A

Chief Medical Officer

2017-02-01

Sell

$30.00

-$29,852

-2%

Griffith Christopher M.

VP Corp. Dev., Strategy

2017-01-17

Sell/Option

$29.11

-$37,937

-3%

Wiggans Thomas G

CEO, COB

2017-01-03

Sell/Option

$31.06

-$248,505

-55%

Chart and technical

The stock went from $38 last year to around 8 this year and now trades around $10. I would enter this stock already now, given the already large declines. Obviously, this case carries higher risk than the average recommendation.

img src="https://static.seekingalpha.com/uploads/2018/7/6570121_15313037004828_rId12_thumb.jpg" data-width="640" data-height="320" data-og-image-twitter_small_card="true" data-og-image-twitter_large_card="true" data-og-image-twitter_image_post="true" data-og-image-msn="true" data-og-image-facebook="true" data-og-image-google_news="true" data-og-image-google_plus="true" data-og-image-linkdin="true"">>

Fundamentals

Q1 cash at 289 MUSD (502 incl short-term investments) compared to 296 Q4 (557 incl short-term investments). Market cap 460 MUSD. The company has communicated they have cash sufficient for first half of 2019. That would imply a higher burn rate than historical trend. A lot can happen between now and then, though, with regards to partnership or creating a sales organization to market its now approved drug Qbrexza.

Dec-17

Dec-16

Dec-15

Dec-14

Dec-13

Dec-12

Dec-11

Total Revenues

5

23

7

7

y/y %

-80%

210%

0%

Gross profit

5

23

7

7

Gross margin %

100%

100%

100%

100%

EBITDA

-171.4

-90.5

-77.2

-31.6

EBITDA %

Net income

-303

-89

-78

-32

Cash and equivalents

296

42

107

55

Free cash flow

-104

-75

-49

-32

Seeking Alpha and other articles

SA July 2018: Dermira May Provide Some Upside Potential, Even After Latest FDA Approval

SA March 2018: Dermira Tumbles On Phase 3 Data For Acne, But Hope Remains

OPKO Health

Summary

CEO, COB and majority holder Phillip Frost is buying every day. This is a pure momentum play betting he will continue and eventually buy out the company. I do not like the fundamental news flow from the company, and I believe this is a case of throwing good money after bad money. Not my favorite type of setup, but I guess a limited position could work as a diversifying setup. But watch out if he stops buying. (late addition while writing this article: the last filing is now from 5th of July, it could simply be a delay in reporting given the higher-than-average shares traded and increase in price, but I would wait a couple of days to see new filings).

Basic company Info

OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations.

Industry

Medical Appliance and Equipment

Market cap

3.2 B

Employees

6000

P/S

3.2

Founded

1991

P/E

-

Website

www.opko.com

P/CF

-

Insider trading

Phillip Frost has deep pockets. He seems to be buying almost every day, creating a positive momentum in the stock.

Name

Insider Type

Trade date

Buy/Sell

Price

Value

Own. Chg

Frost Phillip Md Et Al

CEO, COB, 10%

2018-07-03

Buy

$4.75

+$47,501

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-29

Buy

$4.71

+$36,335

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-28

Buy

$4.68

+$93,600

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-27

Buy

$4.75

+$47,500

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-22

Buy

$4.45

+$44,500

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-21

Buy

$4.54

+$136,200

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-19

Buy

$4.32

+$86,300

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-18

Buy

$4.34

+$62,013

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-15

Buy

$4.42

+$44,200

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-11

Buy

$4.22

+$42,200

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-07

Buy

$4.04

+$40,400

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-06-06

Buy

$4.05

+$121,500

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-31

Buy

$3.76

+$14,664

0%

Fishel Robert Scott

Dir

2018-05-29

Buy

$3.73

+$9,333

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-25

Buy

$3.70

+$37,000

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-23

Buy

$3.73

+$149,300

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-22

Buy

$3.73

+$37,300

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-21

Buy

$3.82

+$344,096

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-18

Buy

$4.04

+$403,789

0%

Fishel Robert Scott

Dir

2018-05-14

Buy

$4.79

+$8,622

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-04

Buy

$3.14

+$81,540

0%

Fishel Robert Scott

Dir

2018-05-04

Buy

$3.14

+$15,700

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-03

Buy

$3.09

+$159,998

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-02

Buy

$3.15

+$158,630

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-05-01

Buy

$3.05

+$95,210

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-30

Buy

$3.08

+$231,126

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-26

Buy

$3.03

+$96,449

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-25

Buy

$2.99

+$165,342

0%

Fishel Robert Scott

Dir

2018-04-25

Buy

$2.97

+$37,125

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-24

Buy

$2.97

+$222,641

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-23

Buy

$3.04

+$227,655

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-20

Buy

$3.12

+$187,490

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-19

Buy

$3.17

+$31,700

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-16

Buy

$3.02

+$150,950

0%

Fishel Robert Scott

Dir

2018-04-16

Buy

$3.01

+$45,100

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-13

Buy

$2.99

+$89,800

0%

Fishel Robert Scott

Dir

2018-04-13

Buy

$3.02

+$30,200

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-12

Buy

$3.04

+$197,300

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-11

Buy

$3.06

+$131,727

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-10

Buy

$3.06

+$111,706

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-09

Buy

$3.04

+$243,088

0%

Fishel Robert Scott

Dir

2018-04-06

Buy

$3.16

+$31,600

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-06

Buy

$3.10

+$186,152

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-05

Buy

$3.25

+$32,500

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-04-03

Buy

$3.00

+$458,790

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-03-28

Buy

$3.07

+$245,868

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-03-27

Buy

$3.25

+$279,689

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-03-26

Buy

$3.19

+$83,055

0%

Frost Phillip Md Et Al

CEO, COB, 10%

2018-03-23

Buy

$3.27

+$81,700

0%

Chart and technical

Slight exhaustion signs recently, which is why I would await a pullback before entering. This pause should also be used to confirm Frost's continued buying. Without his purchases, the stock will pull back hard.img src="https://static.seekingalpha.com/uploads/2018/7/6570121_15313037004828_rId16_thumb.jpg" data-width="640" data-height="320" data-og-image-twitter_small_card="true" data-og-image-twitter_large_card="true" data-og-image-twitter_image_post="true" data-og-image-msn="true" data-og-image-facebook="true" data-og-image-google_news="true" data-og-image-google_plus="true" data-og-image-linkdin="true"">>

Fundamentals

Not much to be impressed with here, negative y/y revenues and decline in gross margin. Also, the free cash flow is negative while the cash position in Q1 was held up by increasing debt.

Dec-17

Dec-16

Dec-15

Dec-14

Dec-13

Dec-12

Dec-11

Total Revenues

1,068

1,222

492

91

13

47

28

y/y %

-12.6%

148.5%

439.7%

617.3%

-73.0%

67.9%

Gross profit

447

610

257

43

13

19

11

Gross margin %

42%

50%

52%

47%

100%

41%

38%

EBITDA

-192.4

15.6

-63.3

-122.4

-15.3

-29.2

-20.9

EBITDA %

-18%

1%

-13%

-134%

-120%

-62%

-75%

Net income

-309

-25

-30

-172

-115

-31

-4

Cash and equivalents

92

169

194

69

186

27

72

Free cash flow

-139

14

153

-95

-18

-27

-16

Seeking Alpha and other articles

Motley Fool Aug. 2017: OPKO Health's Biggest Believer: CEO Phillip Frost Puts His Money Where His Mouth Is

SA: Feb. 2018: OPKO Health: New Signs Of Chaos In Key Diagnostics Division

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in ALL OF THE ABOVE over the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This news has been published by title Weekly Insider Trading, July 10

If the page you entrance is mistake or not way in perfectly, entertain visit the indigenous web in source CLICK HERE

Thank you for your visit to our website, hopefully the counsel we convey is useful, reach not forget to part and subscribe our web to get more information.

[TAG]12169